Patients with HER-2 positive early breast cancer with residual invasive disease after neoadjuvant therapy were randomly ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine ...

For patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer, adjuvant trastuzumab ...

Adjuvant ado-trastuzumab emtansine significantly prolonged survival compared with trastuzumab for certain women with ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

Trastuzumab pamirtecan is under clinical development by BioNTech and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition success ...

Phase 3 data support pyrotinib plus trastuzumab and docetaxel “as a well-established and effective treatment strategy,” according to Binghe Xu, MD.

Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Breast Cancer.

“We observed that the majority of our trastuzumab resistant cell lines remain sensitive to lapatinib, providing further evidence that these two agents have independent mechanisms of resistance.

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Subcutaneous administration ...

trastuzumab deruxtecan (T-DXd; Enhertu) or physician's choice of chemotherapy. Patients in the T-DXd group had a median progression-free survival (PFS) of 9.9 months compared with 5.1 months among ...

Potential practice-changing therapies in gynecologic cancer include the emergence of carboplatin, paclitaxel, and PD-1 ...